Zunveyl® (benzgalantamine) – New drug approval
July 29, 2024 - Alpha Cognition announced the FDA approval of Zunveyl (benzgalantamine), for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.
July 29, 2024 - Alpha Cognition announced the FDA approval of Zunveyl (benzgalantamine), for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.